论文部分内容阅读
评价细胞因子诱导的杀伤细胞 (cytokineinducedkiller ,CIK)治疗白血病合并丙型病毒性肝炎患者的有效性及安全性。方法 :采用血细胞分离机大量采集患者的外周血单个核细胞 ,再用抗CD3单抗、白细胞介素2、干扰素γ培养 10d左右 ,然后将细胞洗涤后经静脉回输给患者。结果 :12例患者在CIK治疗后其血清HCV RNA均有一段时间转阴 ,其中 7例持续转阴至报告时 (观察时间为 7～ 5 6个月 ) ,2例持续转阴 6个月后因难治性白血病死亡。CIK治疗后 ,6例患者肝功能 (ALT和 /或BIL)均有明显改善 ;另 6例肝功能持续正常。CIK输注后除一过性发热 ,畏寒、疲乏外 ,无其它严重副作用。结论 :自体CIK细胞治疗具有明显抑制甚至清除白血病患者合并丙型肝炎病毒感染的作用 ,可明显改善患者的肝功能 ,静脉输注安全。
To evaluate the efficacy and safety of cytokine-induced killer (CIK) in the treatment of patients with leukemia and hepatitis C. Methods: A large number of patients’ peripheral blood mononuclear cells were collected with a blood cell separator, and then cultured with anti-CD3 monoclonal antibody, interleukin-2 and interferon gamma for about 10 days. The cells were then washed and returned to the patient by intravenous infusion. Results: In the 12 patients, serum HCV RNA was negative for some time after CIK treatment, of which 7 cases continued to be negative until the time of reporting (observation time was 7 to 56 months), and 2 cases continued to turn negative after 6 months. Death from refractory leukemia. After CIK treatment, liver function (ALT and/or BIL) were significantly improved in 6 patients; liver function remained normal in the other 6 patients. After the CIK infusion, there was no other serious side effects except for transient fever, chills and fatigue. Conclusion : Autologous CIK cell therapy can significantly inhibit or even eliminate the infection of hepatitis C virus in patients with leukemia. It can significantly improve liver function and safety of intravenous infusion.